慢性肾病肾素-血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂双重阻断肾素-血管紧张素系统

Joon Ho Song, Seok Ho Cha, Seong Bin Hong, Dae Hyeok Kim
{"title":"慢性肾病肾素-血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂双重阻断肾素-血管紧张素系统","authors":"Joon Ho Song,&nbsp;Seok Ho Cha,&nbsp;Seong Bin Hong,&nbsp;Dae Hyeok Kim","doi":"10.1097/01.hjh.0000220414.99610.6b","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the renoprotective effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), many patients with chronic kidney disease develop end-stage kidney disease. Combination treatment with an ACEI and an ARB is a recently introduced approach to obtain more complete blockade of the renin-angiotensin system, based on the different mechanisms of action of the two classes of drug. To assess the shortcomings of single treatment with ACEIs and ARBs, and the potential benefits of combination treatment, we reviewed the experimental and clinical evidence suggesting that combination treatment offers more complete blockade of the renin-angiotensin system and identified areas in which further research is necessary to confirm the benefits of combination treatment. The available data suggest that combination treatment with an ACEI and an ARB has a greater renoprotective effect than either drug alone. In addition, more recent data have shown that combination treatment is more potent in suppressing renal fibrosis, and is well tolerated in patients with advanced chronic kidney disease. Clinical trials with rigorous endpoints are needed to further establish the benefits of combination treatment in renal protection.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"24 1","pages":"S101-6"},"PeriodicalIF":0.0000,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000220414.99610.6b","citationCount":"23","resultStr":"{\"title\":\"Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.\",\"authors\":\"Joon Ho Song,&nbsp;Seok Ho Cha,&nbsp;Seong Bin Hong,&nbsp;Dae Hyeok Kim\",\"doi\":\"10.1097/01.hjh.0000220414.99610.6b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite the renoprotective effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), many patients with chronic kidney disease develop end-stage kidney disease. Combination treatment with an ACEI and an ARB is a recently introduced approach to obtain more complete blockade of the renin-angiotensin system, based on the different mechanisms of action of the two classes of drug. To assess the shortcomings of single treatment with ACEIs and ARBs, and the potential benefits of combination treatment, we reviewed the experimental and clinical evidence suggesting that combination treatment offers more complete blockade of the renin-angiotensin system and identified areas in which further research is necessary to confirm the benefits of combination treatment. The available data suggest that combination treatment with an ACEI and an ARB has a greater renoprotective effect than either drug alone. In addition, more recent data have shown that combination treatment is more potent in suppressing renal fibrosis, and is well tolerated in patients with advanced chronic kidney disease. Clinical trials with rigorous endpoints are needed to further establish the benefits of combination treatment in renal protection.</p>\",\"PeriodicalId\":16074,\"journal\":{\"name\":\"Journal of hypertension. Supplement : official journal of the International Society of Hypertension\",\"volume\":\"24 1\",\"pages\":\"S101-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/01.hjh.0000220414.99610.6b\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of hypertension. Supplement : official journal of the International Society of Hypertension\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.hjh.0000220414.99610.6b\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.hjh.0000220414.99610.6b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 23

摘要

尽管血管紧张素转换酶抑制剂(ACEIs)和血管紧张素II受体阻滞剂(ARBs)具有肾保护作用,但许多慢性肾病患者发展为终末期肾病。基于两类药物不同的作用机制,ACEI和ARB联合治疗是最近引入的一种更完全阻断肾素-血管紧张素系统的方法。为了评估acei和arb单独治疗的缺点,以及联合治疗的潜在益处,我们回顾了实验和临床证据,表明联合治疗可以更完全地阻断肾素-血管紧张素系统,并确定了需要进一步研究以确认联合治疗益处的领域。现有数据表明,ACEI和ARB联合治疗比单独使用任何一种药物具有更大的肾保护作用。此外,最近的数据显示,联合治疗在抑制肾纤维化方面更有效,并且在晚期慢性肾病患者中耐受性良好。需要有严格终点的临床试验来进一步确定联合治疗在肾保护方面的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.

Despite the renoprotective effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), many patients with chronic kidney disease develop end-stage kidney disease. Combination treatment with an ACEI and an ARB is a recently introduced approach to obtain more complete blockade of the renin-angiotensin system, based on the different mechanisms of action of the two classes of drug. To assess the shortcomings of single treatment with ACEIs and ARBs, and the potential benefits of combination treatment, we reviewed the experimental and clinical evidence suggesting that combination treatment offers more complete blockade of the renin-angiotensin system and identified areas in which further research is necessary to confirm the benefits of combination treatment. The available data suggest that combination treatment with an ACEI and an ARB has a greater renoprotective effect than either drug alone. In addition, more recent data have shown that combination treatment is more potent in suppressing renal fibrosis, and is well tolerated in patients with advanced chronic kidney disease. Clinical trials with rigorous endpoints are needed to further establish the benefits of combination treatment in renal protection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信